Amedra announced that Albenza 200mg (abendazole tablets) is now available in a 2-count bottle, in addition to the original 28-count bottle.
Albenza tablets were approved by the FDA in 1996. It is indicated in parenchymal neurocysticercosis from active lesions due to Taenia solium (pork tapeworm), cystic hydatid disease of the liver, lung, and peritoneum due to Echinococcus granulosus (dog tapeworm). Albenza, a benzimidazole, exerts its effects by inhibiting mitochondrial fumarate reductase, decreasing glucose transport, and the uncoupling of oxidative phosphorylation.
For more information call (800) 850-2719 or visit www.amedrapharma.com.